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Advanced glycosylation end products induce inducible nitric
oxide synthase (iNOS) expression via a p38 MAPK-dependent
pathway.
Background. Advanced glycosylation end products (AGEs)
accumulation in tissue has been implicated in diabetic related
complications, including diabetic nephropathy. Activation of
peroxisome proliferator activated receptor-c (PPAR-c) ame-
liorates diabetic nephropathy.
Methods. In the present study, we investigated the effects
of AGEs on inducible nitric oxide synthase (iNOS) expression
and nitric oxide production, and the effects of rosiglitazone, an
activator of PPAR-c, on AGE-induced iNOS expression and
nitrite release in glomerular mesangial cells.
Results. AGEs caused a dose- and time-dependent increase
of iNOS induction and nitrite accumulation in mesangial cells. A
protein tyrosine kinase inhibitor (genistein), or a p38 mitogen-
activated protein kinase (MAPK) inhibitor (SB203580) sup-
pressed AGE-induced iNOS expression and nitrite release from
mesangial cells. Addition of bovine serum albumin (BSA)-
AGEs to mesangial cells increased p38 MAPK activities. Ac-
tivation of PPAR-c by rosiglitazone inhibited AGE-induced
iNOS expression, nitrite release, and p38 MAPK activation in
mesangial cells. AGE-stimulated nitrite release was attenuated
by pretreatment with anti-tumor necrosis factor-a (TNF-a) and
anti-transforming growth factor-b (TGF-b) antibodies. AGE-
induced iNOS expression was inhibited by treatment with a
nuclear factor-jB (NF-jB) inhibitor, pyrrolidone dithiocarba-
mate. Addition of BSA-AGEs to mesangial cells stimulated p65
NF-jB translocation from the cytosol to the nucleus.
Conclusion. These data suggest that cytokine release, NF-
jB and p38 MAPK-dependent pathways may play a role
in AGE-induced iNOS expression and subsequent nitric ox-
ide production in mesangial cells. Rosiglitazone may prevent
AGE-induced iNOS expression by interfering with p38 MAPK
activity.
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Advanced glycosylation end products (AGEs) are
formed by nonenzymatic “Maillard reaction” [1] and
have been related to the pathogeneses of diabetic com-
plications and aging [2]. In diabetic kidney, AGEs were
detected in the mesangial area in glomeruli, which were
associated with a paralleled increased of inducible nitric
oxide synthase (iNOS)-positive cells and intraglomeruli
NO2−/NO3− production [3]. AGEs have been shown to
stimulate iNOS expression and nitric oxide release from
a variety of cell lines [4–6]. However, the mechanisms
by which AGEs induce iNOS expression in glomerular
mesangial cells have not been elucidated.
Recently, many AGE-specific receptors/binding pro-
teins have been identified in mesangial cells [7–9].
Activation of AGE receptors results in both removal of
irreversibly glycosylated molecules, and the activation of
cell functions, including secretion of a variety of cytokines
[10]. AGEs stimulate the secretion of tumor necrois
factor-a (TNF-a), transforming growth factor-b (TGF-b)
may activate mitogen-activated protein kinase (MAPK)
and nuclear factor-jB (NF-jB)-dependent pathways and
subsequently induce the expression of proinflammatory
mediators such as iNOS [11]. There are three important
groups of MAPKs, including p44/42 MAPK, also known
as extracellular signal-regulated kinase 1/2 (ERK1/2),
stress-activated protein kinase (SAPK)/c-jun N-terminal
kinase (JNK), and p38 MAPK. The p44/42 MAPK path-
way is preferentially activated by growth factors and
mitogens, whereas the SAPK/JNK and p38 MAPK path-
ways are preferentially activated by inflammatory cy-
tokines and various forms of stress [12]. Engagement
of AGE receptors by AGEs activates a p21 Ras and
MAPK-dependent signal transduction pathway [13]. We
previously demonstrated that AGEs may activate protein
tyrosine kinase to induce p38 MAPK activation, which
in turn induces iNOS expression in C6 glioma cells [6]
and cyclooxygenase-2 (COX-2) expression in RAW 264.7
cells [14]. These findings suggest a role for the p38 MAPK
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pathway as important signaling mechanisms underlying
the AGE-induced iNOS expression in renal mesangial
cells.
Peroxisome proliferator activated receptor-c
(PPAR-c) is a nuclear hormone transcription factor
that regulates gene associated with lipid and glucose
metabolism. PPAR-c can be activated by the antidiabetic
thiazolidinediones (TZDs) and the natural occurring
ligand, the J series of prostaglandins. Activation of
PPAR-c ameliorates diabetic nephropathy and reduced
mesangial cell DNA synthesis without affecting mesan-
gial cell viability [15]. Activation of PPAR-c also inhibits
the proinflammatory pathways, including the cytokine
secretion [16, 17] and iNOS expression [18, 19] in a
variety of cell lines. The murine iNOS promoter contains
24 transcriptional factor binding sites, including those
for NF-jB, activator protein-1 (AP-1), cyclic adenosine
monophosphate (cAMP)-responsive element binding
protein (CREB), and the ets family of transcription
factors. Some of these transcription factors are regulated
by p38 MAPK. However, whether p38 MAPK plays a
role in inhibition of AGE-induced iNOS expression by
rosigitazone has not been investigated.
In the present study, we investigate the effects of bovine
serum albumin (BSA)-AGEs on iNOS expression and ni-
tric oxide release in glomerular mesangial cell. We found
that BSA-AGEs stimulated a dose- and time-dependent
up-regulation of both iNOS protein expression and ni-
trite accumulation. The AGE-stimulated effects were
blocked by pretreatment of cells with NF-jB inhibitor
or anti-TNF-a and anti-TGF-b antibodies, suggesting
AGE-stimulated iNOS expression and nitric oxide pro-
duction is at least in part secondary to cytokine secretion
and NF-jB activation. The AGE-induced iNOS expres-
sion was blocked by pretreatment of mesangial cells with
rosiglitazone, the PPAR-c activator, or SB203580, the p38
MAPK inhibitor. Given rosiglitazone blocked nitric ox-
ide production, iNOS protein expression, and p38 MAPK
activation in AGE-stimulated mesangial cells, these data
suggest that rosiglitazone may prevent AGE-induced
iNOS expression and subsequent nitric oxide produc-
tion in mesangial cells by interfering with p38 MAPK
activation.
METHODS
Materials
Affinity-purified polyclonal antibodies to iNOS, a-
tubulin, a-smooth muscle actin (a-SMA), p65 NF-jB,
and p38 MAPK were obtained from Transduction Labo-
ratory (Lexington, KY, USA). Genistein, FPT inhibitor
II, PD 98059, pyrrolidone dithiocarbamate (PDTC),
and SB 203580 were purchased from Calbiochem (San
Diego, CA, USA). Dulbecco’s modified Eagle’s medium
(DMEM), heat-inactive fetal calf serum (FCS) and
horse serum, L-glutamine, sodium pyruvate, penicillin,
and streptomycin were purchased from Life Technolo-
gies (Gaithersburg, MD, USA). 5-Bromo-4-chloro-3-
indolyl-phosphate/4-nitro blue tetrazolium substrate was
purchased from Kirkegaard & Perry Laboratories
(Gaithersburg, MD, USA). Protease inhibitor cocktail
tablets were purchased from Boehringer Mannheim
(Mannheim, Germany). The p38 MAPK assay kit was
purchased from New England Biolabs (Beverly, MA,
USA). All other chemicals were purchased from Sigma
Chemical Co. (St. Louis, MO, USA).
Preparation of albumin-derived AGEs
and N(epsilon)-(carboxymethyl)-lysine (CML)
BSA-derived AGEs were prepared by incubating 1 M
glucose with 50 mg/mL BSA in phosphate buffered saline
(pH 7.4) for at least 6 months. All incubations were per-
formed under sterile conditions in the dark at 37◦C. Af-
ter incubation, unreacted sugars were removed before
assay by extensive dialysis against phosphate-buffered
saline (PBS). BSA-AGEs solution was filter sterilized and
stored in a freezer at (−20◦C) before use. CML was pre-
pared as described [20]. Briefly, 2mg/mL of BSA was incu-
bated at 37◦C for 24 hours with 0.75 mol/L glyoxylic acid
and 0.3 mol/L NaCNBH3 in 0.5 mol/L sodium phosphate
buffer, pH 7.4. The preparation was dialyzed against PBS
to remove the unreacted chemicals. In this CML-BSA
preparation, the extent of modification was 34.5 mol of
CML/mol of BSA [20].
Culture of rat mesangial cells and preparation
of nuclear extracts and cell lysates
Glomerular mesangial cells from an SV40 transgenic
mouse (ATCC CRL-1927) were cultured in DMEM
supplemented with 13.1 mmol/L NaHCO3, 13 mmol/L
glucose, 2 mmol/L glutamine, 10% heat-inactive FCS,
and 10% horse serum and penicillin (100 U/mL)/
streptomycin (100 mg/mL). Cells were attached to a Petri
dish after a 24-hour incubation. Cells were plated at a con-
centration of 1 × 105 cells/mL and used for experiments
when they reached 80% confluency. All reagents were
added directly to the culture at a volume of 100 lL/10 mL
medium. Cultures were maintained in a humidified incu-
bator in 5% CO2 at 37◦C. Cells were harvested, chilled on
ice, and washed three times with ice cold PBS. Subsequent
procedures proceeded on ice unless otherwise specified.
Nuclear extracts were prepared as described previously
[21]. Briefly, cultured mesangial cells were treated with
BSA-AGEs (300 lg/mL) for various time periods. Cells
were harvested and incubated in hypotonic buffer con-
taining (mmol/L) HEPES 10 (pH 7.9), KCl 10, dithiothre-
itol (DTT) 0.5, phenylmethylsulfonyl fluoride (PMSF) 2,
and 1% (wt/vol) aprotinin, and 10 lg/mL leupeptin, for
15 minutes on ice, and vigorously vortexed for 10 seconds.
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Nuclei were pelleted by centrifugation at 15,000 ×g for
1 minute. The supernatants containing cytosolic proteins
were collected. Pellets were resuspended in hypertonic
buffer containing (mmol/L) HEPES 20 (pH 7.6), MgCl2
1.5, ethylenediaminetetraacetic acid (EDTA) 4, DTT 0.5,
PMSF 2, and 25% glycerol, 1% (wt/vol) aprotinin, and
10 lg/mL leupeptin, for 30 minutes on ice. The super-
natants containing nuclear proteins were collected by
centrifugation at 15,000 ×g for 2 minutes and stored
at −70◦C. For cell lysate preparation, cells were lysed
by adding lysis buffer containing 10 mmol/L Tris HCl
(pH 7.5), 1 mmol/L ethylene glycol tetraacetate (EGTA),
1 mmol/L MgCl2, 1 mmol/L sodium orthovanadate,
1 mmol/L DTT, 0.1% mercaptoethanol, 0.5% Triton X-
100, and the protease inhibitor cocktails (final concentra-
tions 0.2 mmol/L PMSF, 0.1% aprotinin, and 50 lg/mL
leupeptin). Cells adhering to the plates were scraped off
using a rubber policeman and stored at −70◦C for further
measurements.
Polyacrylamide gel electrophoresis (PAGE)
and Western blotting
Electrophoresis was ordinarily carried out on differ-
ent percentages of sodium dodecyl sulfate (SDS)-PAGE.
Following electrophoresis, proteins on the gel were elec-
trotransferred onto a nitrocellulose or polyvinyldiflu-
oride (PVDF) membrane. After transfer, the PVDF
paper was washed once with PBS and twice with PBS plus
0.1% Tween 20. The PVDF membrane was then blocked
with blocking solution containing 3% BSA in PBS con-
taining 0.1% Tween 20 for 1 hour at room temperature.
The PVDF membrane was incubated with a solution
containing primary antibodies in the blocking buffer
for 2 hours. Finally, the PVDF papers were incubated
with enzyme-linked secondary antibodies for 1 hour and
then visualized by incubating with colorigenic substrate
(nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-
phosphate) (Sigma Chemical Co.) or developed using
a chemiluminescence kit (Amersham, Buckinghamshire,
UK), and the immunoreactive bands were visualized by
autoradiography.
Measurement of nitrite formation in mesangial
cells cultures
Confluent mesangial cell cultures in 35 mm Petri dishes
were incubated in fresh medium for 24 hours under the
experimental conditions as indicated in the Results sec-
tion. Nitric oxide production in culture supernatant was
assayed by measuring nitrite, its stable degradation prod-
uct, using the Griess reagent. DMEM was changed to
phenol red-free medium before the cells were treated
with 300 lg/mL BSA-AGE. After 24 hours of incubation,
the isolated supernatant was centrifuged and mixed with
an equal volume of Griess reagent (1% sulfanilamide,
0.1% naphthylethylene diamine dihydrochloride, and 5%
phosphoric acid) and incubated at room temperature for
10 minutes. The absorbance was measured at 550 nm in
a microplate reader. Sodium nitrite (NaNO2) was used
as a standard. A blank was prepared for each experi-
mental condition in the absence of mesangial cells, and
the absorbance was subtracted from that obtained in the
presence of cells.
Measurement of p38 MAPK activity
Glomerular mesangial cells were lysed and p38 MAPK
activity was assayed using a commercial kinase assay
kit (New England Biolabs, Beverly, MA, USA). Briefly,
cells were lysed in lysis buffer containing 20 mmol/L
Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1
mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L sodium py-
rophosphate, 1 mmol/L b-glycerolphosphate, 1 mmol/L
Na3VO4, 1 lg/mL leupeptin, and 1 mmol/L PMSF.
Cell lysates were then immunoprecipitated using im-
mobilized phospho-p38 MAPK kinase (Thr180/Tyr182)
monoclonal antibody. Pellets obtained from immuno-
precipitation were suspended and incubated with kinase
buffer containing 25 mmol/L Tris (pH 7.5), 5 mmol/L b-
glycerolphosphate, 2 mmol/L DTT, 0.1 mmol/L Na3VO4,
and 10 mmol/L MgCl2, supplemented with 200 lmol/L
adenosine triphosphate (ATP), and 2 lg activating tran-
scription factor 2 (ATF-2) fusion protein. The reac-
tion was stopped by the addition of sample buffer and
was subjected to 10% PAGE. After transfer, the PDVF
membrane was incubated with buffer containing anti-
phospho-ATF-2 (Thr71) antibody, followed by buffer
containing horseradish peroxidase-conjugated secondary
antibody. The membrane was developed using Lu-
miGLO chemiluminescent reagent, and the immunore-
active bands were visualized by autoradiography.
Statistical analysis
All data are expressed as the mean ± SEM. Compar-
isons between groups were made by Student t test. A
difference between groups of P < 0.05 was considered
significant.
RESULTS
Ages stimulated a dose-dependent increase in nitric
oxide release and iNOS expression in mesangial cells
Exposure of mesangial cells to AGEs stimulates nitrite
production in dose- (Fig. 1A) and time-dependent man-
ners (Fig. 2A). The endothelial cells (EC50) of AGEs-
stimulated nitrite production was about 20 lg/mL, with
the maximum at about 300 lg/mL of AGEs at 24 hours
(Fig. 1A). AGEs induced the expression of the 130 kD
iNOS expression in mesangial cells in a dose-dependent
manner (Fig. 1B). The nitrite accumulation and iNOS
expression was apparent of 2 hours and accumulated
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Fig. 1. Concentration-dependent increase of
nitrite accumulation caused by bovine serum
albumin-advanced glycation end products
(BSA-AGEs) in rat mesangial cells. (A)
Mesangial cells were incubated with various
concentrations of BSA-AGEs for 24 hours,
then the medium was removed and ana-
lyzed for nitrite accumulation from rat mesan-
gial cells. Data represent mean ± SEM of
three independent experiments done in trip-
licate. (B) The cells were lysed and cell lysate
subjected to Western blot analysis using in-
ducible nitric oxide synthase (iNOS)-specific
antibody. (C) Mesangial cells were incubated
with various concentrations of N(epsilon)-
(carboxymethyl)-lysine (CML) for 24 hours,
the cells were lysed and cell lysate subjected
to Western blot analysis using iNOS-specific
antibody. The equal loading in each lane was
demonstrated by the similar intensities of
a-tubulin.
thereafter (Fig. 2B). CML is the major AGE detected
in mesangium and in renal basal membranes in diabetic
nephropathy. Incubation of glomerular mesangial cells
with CML induced iNOS expression in a dose-dependent
manner (Fig. 1C). The time course of CML-induced iNOS
expression was similar to that of AGE-stimulated re-
sponse (Fig. 2C).
Involvement of MAPK signaling pathway
in AGEs-stimulated iNOS expression and nitrite
production by rat mesangial cells
We previously found that AGEs may activate protein
tyrosine kinase and p38 MAPK, which in turn induces
iNOS expression and nitric oxide production in C6 glioma
cells [6]. To elucidate the mechanisms responsible for
changes in iNOS protein expression, mesangial cells were
incubated with BSA-AGEs alone or in the presence of the
protein tyrosine kinase inhibitor (genistein), or the p38
MAPK inhibitor (SB203580). Pretreatment of the cells
for 30 minutes with genistein (5 to 20 lmol/L) attenu-
ated the AGE-stimulated nitrite release (Fig. 3A) and
iNOS expression (Fig. 3B) in mesangial cells. To deter-
mine whether p38 MAPK activation was involved in the
signal transduction leading to iNOS expression caused by
AGEs, the p38 MAPK inhibitor, SB203580 was used. Pre-
treatment of the cells with SB203580 (2.5 to 10 lmol/L)
suppressed the up-regulated iNOS expression and nitrite
release from mesangial cells (Fig. 4). These data suggest
that protein tyrosine kinase and p38 MAPK are involved
in the induction of iNOS expression and nitrite accumu-
lation by BSA-AGEs.
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Fig. 2. Time-dependent increase of nitrite
accumulation caused by bovine serum
albumin-advanced glycation end products
(BSA-AGEs) in rat mesangial cells. (A) Rat
mesangial cells were incubated with BSA-
AGEs (300 lg/mL) for various time intervals
then the medium was removed and analyzed
for nitrite accumulation from rat mesangial
cells. Data represent mean ± SEM of three
independent experiments done in triplicate.
(B) The cells were lysed and cell lysate
subjected to Western blot analysis using in-
ducible nitric oxide synthase (iNOS)-specific
antibody. (C) Mesangial cells were incubated
with N(epsilon)-(carboxymethyl)-lysine (CML)
(3 lmol/L) for different time periods, the
cells were lysed and cell lysate subjected to
Western blot analysis using iNOS-specific
antibody. The equal loading in each lane was
demonstrated by the similar intensities of
a-tubulin.
Activation of p38 MAPK by BSA-AGEs
in mesangial cells
The data in Figure 4 suggested that the p38 MAPK ac-
tivated pathway might contribute to the signaling mech-
anism for AGE-induced iNOS expression in mesangial
cells. This notion was further supported by the facts that
p38 MAPK activity was stimulated by BSA-AGEs in
mesangial cells. As shown in Figure 5A, addition of BSA-
AGEs to mesangial cells stimulated p38 MAPK activ-
ity as determined by immunocomplex kinase assay using
ATF-2 as substrate. The p38 MAPK was transiently ac-
tivated within 5 minutes, maximum at about 1 hour, and
decreased at 2 hours. Western blot analysis using anti-
p38 MAPK indicated that the total protein expression
of p38 MAPK was unaffected by BSA-AGEs induction
(Fig. 5A). The activation of p38 MAPK by BSA-AGEs
was inhibited by treatment of mesangial cells with genis-
tein (20 lmol/L), SB203580 (10 lmol/L), but not farne-
syl protein transferase (FPT) inhibitor II (20 lmol/L) for
30 minutes before the addition of 300 lg/mL BSA-AGEs
(Fig. 5B).
Rosiglitazone inhibits AGE-induced iNOS
expression and p38 MAPK activation
Activation of PPAR-c has been shown to inhibit iNOS
expression in mesangial cells [19]. To examine whether
AGE-induced iNOS expression was inhibited by the
PPAR-c activator, rosiglitazone, cells were pretreated
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Fig. 3. Effects of the tyrosine kinase in-
hibitor, genistein, on advanced glycation end
products (AGEs)-induced inducible nitric
oxide synthase (iNOS) expression and nitrite
release from rat mesangial cells. Cells were
pretreated with genistein (5 to 20 lmol/L) for
30 minutes before the addition of 300 lg/mL
bovine serum albumin (BSA)-AGEs and in-
cubated for 24 hours. (A) The medium was re-
moved and analyzed for nitrite accumulation
from rat mesangial cells. Data represent mean
± SEM of three independent experiments
done in triplicate. (B) The cells were lysed
and cell lysate subjected to Western blot anal-
ysis using iNOS-specific antibody. The equal
loading in each lane was demonstrated by the
similar intensities of a-tubulin.
with rosiglitazone (0.3 to 10 lmol/L), ciglitazone (3
to 10 lmol/L), troglitazone (3 to 10 lmol/L), or 15-
deoxy-12,14-prostaglandin J2 (15d-PGJ2)-prostaglandin
J2 (PGJ2) (1 to 2 lmol/L) for 30 minutes before the ad-
dition of 300 lg/mL BSA-AGEs and incubated for 24
hours. As depicted in Figure 6A, the up-regulated iNOS
expression by AGEs was inhibited by pretreatment of
the cells with rosiglitazone, ciglitazone, troglitazone, or
15d-PGJ2. It has to be noted that lower 15d-PGJ2 con-
centrations (1 to 2 lmol/L) were used because higher
concentrations of 15d-PGJ2 (>5 lmol/L) caused cell
apoptosis in cultured mesangial cells. To determine
the PPAR-c dependency, a specific PPAR-c antago-
nist, bisphenol A diglycidyl ether (BADGE), was added
prior to rosiglitazone treatment. As shown in Figure 6B,
the inhibitory effect of rosiglitazone on AGE-induced
iNOS expression did not reversed by BADGE. To de-
termine whether rosiglitazone affected AGE-stimulated
p38 MAPK activity in rat mesangial cells, cells were pre-
treated with rosiglitazone (1 to 10 lmol/L) for 30 minutes
before the addition of 300 lg/mL BSA-AGEs and p38
MAPK activity was determined. As shown in Figure 6C,
rosiglitazone markedly inhibited the AGE-stimulated
p38 MAPK activity in rat mesangial cells. Taken to-
gether, these data confirm that activation of p38 MAPK
plays a crucial signaling mechanism, which regulates
iNOS expression and nitrite accumulation in mesangial
cells. Moreover, it has been demonstrated that incu-
bation of mesangial cells with high glucose concentra-
tion up-regulated the a-SMA expression. As shown in
Figure 6D, BSA-AGEs (300 lg/mL) caused stimulated
expression of SMA in mesangial cells. However, this ef-
fect was not inhibited by rosiglitazone (data not shown).
Roles of cytokine release and NF-kB activation
in age-induced iNOS expression in mesangial cells
To elucidate the role of NF-jB in BSA-AGE-induced
iNOS expression, mesangial cells were incubated with
BSA-AGEs alone or in the presence or absence of
the NF-jB inhibitor, PDTC. PDTC (0.1 to 10 lmol/L)
suppressed AGE-induced iNOS expression dose de-
pendently (Fig. 7A). To confirm whether NF-jB was
activated in mesangial cells, cells were incubated with
BSA-AGEs (300 lg/mL) and p65 NF-jB translocation
from the cytosol to the nucleus was examined. As shown
in Figure 7B, incubation of mesangial cells with BSA-
AGEs (300 lg/mL) for 15 minutes resulted in transloca-
tion of p65 NF-jB from the cytosol to the nucleus. AGEs
have been shown to stimulate secretion of inflammatory
cytokines [3]. To examine whether cytokine release might
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Fig. 4. Effects of the p38 mitogen-activated
protein kinase (MAPK) inhibitor, SB203580,
on advanced glycation end products (AGEs)-
induced inducible nitric oxide synthase
(iNOS) expression and nitrite release from
rat mesangial cells. Cells were pretreated with
SB203580 (2.5 to 10 lmol/L) for 30 min-
utes before the addition of 300 lg/mL bovine
serum albumin (BSA)-AGEs and incubated
for 24 hours. (A) The medium was removed
and analyzed for nitrite accumulation from
rat mesangial cells. Data represent mean ±
SEM of three independent experiments done
in triplicate. (B) The cells were lysed and cell
lysate subjected to Western blot analysis using
iNOS-specific antibody. The equal loading in
each lane was demonstrated by the similar in-
tensities of a-tubulin.
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Fig. 5. Advanced glycation end products
(AGEs) activate p38 mitogen-activated pro-
tein kinase (MAPK) in rat mesangial cells. (A)
Rat mesangial cells were incubated with 300
lg/mL bovine serum albumin (BSA)-AGEs
for various time periods. Cells were lysed and
determined by immunocomplex kinase assay
with ATF-2 as substrate as described in the
Methods section. The equal loading in each
lane was demonstrated by the Western blot
intensities of p38 MAPK. (B) Mesangial cells
were pretreated with genistein (20 lmol/L),
or SB203580 (10 lmol/L), or FPT inhibitor II
(20 lmol/L) for 30 minutes before the addi-
tion of 300 lg/mL BSA-AGEs. After 1-hour
incubation cells were lysed and determined by
immuno-complex kinase assay with ATF-2 as
substrate as described in the Methods section.
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Fig. 6. Effects of the peroxisome proliferator-activated receptor-c (PPAR-c) activator, rosiglitazone, on advanced glycation end products (AGEs)-
induced inducible nitric oxide synthase (iNOS) expression and p38 mitogen-activated protein kinase (MAPK) activity in rat mesangial cells. (A)
Cells were pretreated with rosiglitazone (0.3 to 10 lmol/L), ciglitazone (3 to 10 lmol/L), troglitazone (3 to 10 lmol/L), or 15d-prostaglandin J2
(PGJ2) (1 to 2 lmol/L) for 30 minutes before the addition of 300 lg/mL bovine serum albumin (BSA)-AGEs and incubated for 24 hours or (B)
pretreated with bisphenon A diglycidyl ether (BADGE) (100 or 250 lmol/L) for 15 minutes before the addition of rosiglitazone and BSA-AGEs.
Cells were lysed and cell lysate subjected to Western blot analysis using iNOS-specific antibody. The equal loading in each lane was demonstrated
by the similar intensities of a-tubulin. (C) Cells were pretreated with rosiglitazone (1 to 10 lmol/L) for 30 minutes before the addition of 300 lg/mL
BSA-AGEs. After 1-hour incubation, cells were lysed and determined by immunocomplex kinase assay with ATF-2 as substrate as described in
the Methods section. The equal loading in each lane was demonstrated by the Western blot intensities of p38 MAPK. (D) Mesangial cells were
incubated with BSA-AGEs (300 lg/mL) for different time periods, the cells were lysed and cell lysate subjected to Western blot analysis using
a-smooth muscle–specific antibody.
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Fig. 7. Roles of cytokine secretion and
nuclear factor-jB (NF-jB) activation in
advanced glycation end product (AGE)-
stimulated nitric oxide production and
inducible nitric oxide synthase (iNOS)
expression in mesangial cells. (A) Cells were
pretreated with pyrrolidone dithiocarbamate
(PDTC) (0.1, 1, 10 lmol/L) for 30 minutes
before incubation with bovine serum albumin
(BSA)-AGEs (300 lg/mL) for 24 hours.
Cell lysates were subjected to Western blot
analysis using iNOS-specific antibodies. The
equal loading in each lane was demonstrated
by the similar intensities of a-tubulin. (B)
Cells were incubated with BSA-AGEs (300
lg/mL) for different time periods (15, 30, and
60 minutes). The nuclear extracts and cytosol
were prepared as described in the Methods
section and subjected to Western blot analysis
using p65 NF-jB-specific antibodies. (C)
Mesangial cells were incubated with different
dilutions (1:100 or 1:50) of anti-tumor
necrosis factor-a (TNF-a), anti-transforming
growth factor-b (TGF-b) antibodies or
anti-TNF-a plus anti-TGF-b antibodies for
30 minutes before the addition of 300 lg/mL
BSA-AGEs and incubated for 24 hours. The
medium was then removed, and nitric oxide
production was detected as described in the
Methods section.
be involved in the regulation of mesangial nitric oxide
production, we pretreated cells with anti-TNF-a and anti-
TGF-b antibodies prior to AGE treatment. As shown in
Figure 7C, AGE-stimulated nitric oxide release was in-
hibited by 60% by pretreatment with anti-TNF-a (1:50)
plus anti-TGF-b antibodies (1:50) (P < 0.05).
DISCUSSION
AGE-induced platelet-derived growth factor (PDGF)
and TGF-b synthesis mediates mesangial expansion [22]
and collagen production [23, 24], which is crucial in
the extensive extracellular matrix remodeling that ac-
companies sclerotic processes of the mesangium. In the
present study, we demonstrated that AGEs increase
nitrite production and iNOS expression in glomerular
mesangial cells. Nitric oxide release from mesangial cells
may also modulate the expression of matrix metallo-
proteinase and regulate extracellular matrix remodeling
[25]. Thus, AGE-induced iNOS protein expression may
also be a crucial mediator involved in the pathogene-
ses of diabetic nephropathy. Further, we presented ev-
idence that the AGEs-stimulated iNOS expression was
mediated through a protein tyrosine kinase-p38 MAPK
pathway and that rosiglitazone inhibits AGE-induced
iNOS expression via a p38 MAPK-dependent pathway.
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Understanding the signal transduction pathway that ul-
timately leads to a deleterious effect in the kidney is im-
portant from a therapeutic standpoint.
CML is the major AGE detected in mesangium and in
renal basal membranes in diabetic nephropathy. In the
present studies, we showed that both BSA-AGEs and
CML induce iNOS expression in mesangial cells. In di-
abetic nephropathy, CML was found to colocalized with
the AGE-specific receptor (RAGE) (receptor for AGEs)
in mesangium [8]. Activation of RAGE results in gener-
ation of intracellular oxidative stress and subsequent ac-
tivation of the transcription factor jB in vitro and in vivo
[26–29]. We have recently reported that AGEs may in-
duce iNOS expression through a NF-jB-dependent path-
way [21]. In the present study, we demonstrated that
treatment of mesangial cells with the pharmacologic in-
hibitor of NF-jB, PDTC, inhibited AGE-induced iNOS
expression. We also showed that AGEs stimulate p65
NF-jB translocation from the cytosol to the nuclei. Al-
though we did not test whether rosiglitazone blocks p65
NF-jB translocation, a number of reports have shown
that PPAR-c–mediated mechanisms may interfere with
NF-jB activation [30], or reduce the secretion of in-
flammatory cytokines [31] and thus inhibits iNOS induc-
tion. In agreement we showed that cytokine secretion
may play a role in the induction of iNOS. Collectively,
these data suggest RAGE may play an important role
in mediating AGE-induced iNOS expression in mesan-
gial cells. RAGE is a 35 kD protein belongs to a mem-
ber of the immunoglobulin receptor superfamily. Other
than this receptor type, AGEs can also be recognized by
many other AGE-binding proteins, including scavenger
receptors types I and II, oligosaccharyl transferase-48
(OST-48, AGE-R1), 80K-H phosphoprotein (AGE-R2),
and galectin-3 (AGE-R3). Among these newly iden-
tified AGE-binding proteins, galectin-3 (AGE-R3)
appears to be the most important one in diabetic
nephropathy. Galectin-3 was not detected in rat
mesangium and was selectedly up-regulated in diabetic
mesangium [32]. The p60/AGE-R1 and the p90/AGE-
R2 are only slightly up-regulated or even reduced
in diabetic mesangium [32]. Whether galectin-3 medi-
ates AGE-induced iNOS expression remained to be
determined.
Our results are consistent with a previous report that
showed p38 MAPK is important for induction of iNOS by
interleukin (IL)-1b in glomerular mesangial cells [33]. In
the present study, we found that AGE-stimulated nitrite
release, iNOS expression and p38 MAPK activation were
inhibited by genistein pretreatment, suggesting AGEs
may also mediate its signal through tyrosine phosphoryla-
tion. In agreement, lipopolysaccharide (LPS)-stimulated
iNOS expression is inhibited by the tyrosine kinase
inhibitors in murine macrophages [34] and in retinal
epithelial cells [35]. In rat pulmonary artery smooth mus-
cle cells, activation of the receptor of AGEs triggers a
p21 Ras-dependent MAPK pathway regulated by oxi-
dant stress in rat pulmonary artery smooth muscle cells
[13]. However, the Ras inhibitor, FPT inhibitor II had no
effect on AGE-stimulated p38 MAPK activation in renal
mesangial cells. These results suggest that AGE-induced
iNOS expression may occur via upstream tyrosine phos-
phorylation and p38 MAPK activation, whereas p21 Ras
are not involved in the signaling cascades in mesangial
cells. One possible explanation for this discrepancy is the
difference of cell contexture. For example, p21 Ras and
the p44/42 MAPK are not involved in the signaling cas-
cades in AGE-induced COX-2 expression in RAW 264.7
cells [14].
AGEs induce PPAR-c gene expression in mesangial
cells [36]. Activation of PPAR-c by PPAR-c ligands has
been reported to exert anti-inflamatory activities [37].
Consistently, we demonstrated that rosiglitazone, the
PPAR-c activator, inhibited AGE-induced p38 MAPK
activation and iNOS induction in rat mesangial cells.
Other PPAR-c agonists, including ciglitazone, troglita-
zone, and 15d-PGJ2 have similar inhibitory effects on
AGE-induced iNOS induction in mesangial cells. Our re-
sults conflicts with the observation that a PPAR-c ligand,
ciglitazone, potentiates IL-1b/TNF-a–induced iNOS ex-
pression by threefold by increasing iNOS mRNA stability
[38]. Given several PPAR-c agonists, including 15d-PGJ2,
troglitazone, and cPGI2, have all been shown to display
PPAR-c–independent effects, and the facts that iNOS po-
tentiation does not correlate with the increased PPAR-c
activity [38], the discrepancies may be due to PPAR-c in-
dependent effects. In accordance, we found that in the
presence of PPAR-c antagonist BADGE, rosiglitazone
still inhibits iNOS expression in mesangial cells, suggest-
ing that this effect is PPAR-c independent.
Our results differ from a recent report showing
mesangial cells prepared from MRL/1pr mice, 15d-
PGJ2 blocked nitric oxide production, iNOS protein
expression, and iNOS mRNA transcription, but failed
to inhibit nuclear LPS/interferon-c (IFN-c) stimulated
NF-jB translocation, p44/42 MAPK or p38 MAPK acti-
vation [19]. Because MRL/1pr mice have a highlighted re-
sponse to inflammatory mediators and spontaneous over-
production of nitric oxide [39], the discrepancies of p38
MAPK dependency may be due to the differences in cell
type. Previous studies have shown that inhibitions of LPS-
or cytokine-induced iNOS expression by TZDs are medi-
ated through regulation of the transcription factors AP-1,
STAT, NF-jB, and induction of the heat shock response
[37, 40, 41]. Because some of these transcription factors
are regulated by p38 MAPK, possibly regulation of the
transcription initiation by p38 MAPK mediates AGEs-
stimulated iNOS expression.
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CONCLUSION
AGEs-stimulate iNOS expression is mediated through
activation of NF-jB and p38 MAPK pathway. Further
works are required to elucidate whether other pathways
are involved in mediating the AGEs-mediated inflamma-
tion, which subsequently results in neuronal damage.
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